STRIDE Study : The Effects of semaglutide on functional capacity in pith type 2 diabetes and peripheral arterial disease

Brief description of study

This is a 52 week, randomized, double-blind, placebo-controlled trial comparing semaglutide 1 mg versus placebo both added to standard of care and administered once weekly in subjects with Type 2 Diabetes Mellitus with Intermittent Claudication.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
type 2 diabetes,peripheral arterial disease,PAD,type 2 diabetes,peripheral arterial disease,PAD
Age: Between 18 Years - 99 Years
Gender: All

Male or Female Type 2 Diabetes 18 years of age or older peripheral arterial disease

Updated on 09 Mar 2024. Study ID: 848387

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).